![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Saturday, November 13, 2021 9:26:09 AM
What transpired is a more aggressive but amazingly safe therapy. The new method was just patented, because the best version was finally determined and able to be produced through partial maturation/activation, and in a percentage of individual cases, if needed, adjusted to meet the required threshold for quality and cytokine production.
Now, yes, now they could be starting a phase ii/iii, but because the technology is so closely associated with DCVax-l, if they did start before L approval, any hiccups Direct met along the clinical trial path (remember, it is more aggressive) might slow down approval of L.
So, L, whether you know it or not, is now more efficacious against GBM than it was before, because in the past year, the definition of GBM changed, and that change happened to match L’s immunotherapeutic method of action even better. If L would have sputtered out of the gates, NWBO might fall into the Dendreon trap. Dendreon neither had a lower cost manufacturing system, nor did it really stand out among its competition.
On the other hand, L has developed a lower cost manual manufacturing process, and in the foreseeable future will transition to an even lower cost closed system automated manufacturing system. Now, what about its competition for GBM therapy at this late moment in time? Lomustine and Avastin are essentially out. Optune leads to a higher rate of distant tumors and can’t prove true long term efficacy. Monotherapy with Temodar can only somewhat help methylated MGMT GBM (not unmethylated) (under the new GBM definition), monotherapy with Checkpoint inhibitors failed again and again.
The wait for DCVax-l has been intolerable, but it is now set up to succeed on efficacy, economic manufacturing and against competition like never before.
I do believe it will succeed on all these levels now, and its heralded success will likely initially allow DCVax-Direct to enter the scene on L’s coattails. Ultimately, in a few years to come, Direct could eliminate the need for surgery in many cases and many cancers, not only due to its MOA, but also because the ability to detect 50 types of cancer much earlier has exponentially improved this year. Combine that with the power of Direct, and the future looks very very bright.
And I believe in the future
We shall suffer no more
Maybe not in my lifetime
But in yours I feel sure — Paul Simon
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM